Oracle is set to report its earnings after the market closes on Wednesday, with the stock having risen nearly 36% over the past three months. Analysts anticipate a potential price movement of 12% following the earnings release, as indicated by the high volume of call options traded compared to puts.
In the pharmaceutical sector, Jim Cramer expressed a favorable view on drug stocks, noting that the S&P Health Care index rose 1.3% on Tuesday, although it remains 3.5% below its February peak. Cramer highlighted his recent purchase of Johnson & Johnson, which has appreciated 6% since June 1, despite being down 6% from its March high.
Target's shares have increased 52% since November but are currently down 5% from their April high, reflecting some volatility. Meanwhile, the iShares MSCI Italy ETF reached a new high, driven by strong performances from major Italian companies, closing the day up 1.5% and 11% higher over the past three months.
Lastly, Trulieve, the first U.S. cannabis company to list on the NYSE, experienced a significant drop of 11% after hitting a new high, although it remains up 24% for June, indicating the potential for both growth and volatility in the cannabis sector